Wesley Armstrong, BS, UCLA, Los Angeles, CA, discusses a randomized Phase III trial (NCT03582774) investigating the impact of PSMA PET on salvage radiotherapy management for prostate cancer patients after prostatectomy. The primary endpoint of the trial has not yet been reached, however the secondary endpoints show promising data for the use of PSMA PET to assist treatment management. Mr Armstrong also discusses how the study design reflected real-world treatment management decisions. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.